Inflammatory Bowel Disease
Biologic agents increase the risk of opportunistic infection, but do not increase the risk of serious infection or malignancy.
Patients with Crohn disease who ate high-fiber foods were 40% less likely to have a disease flare.
A condition prone to recurrence, Crohn disease has a complicated presentation and pathophysiology, but multiple treatment options are available.
Entyvio can be used to treat ulcerative colitis and Crohn disease in adults who did not have success with other treatments.
People with airway diseases are more likely to have inflammatory bowel disease.
The FDA has approved vedolizumab for patients with inadequate response to conventional therapies.
No difference in hypotension between low-, high-dose steroids for IBD patients undergoing major colorectal surgery.
Earlier exposure to antianaerobic antibiotics during childhood tied to greater risk for inflammatory bowel disease.
Adalimumab induction and maintenance was shown to be safe and effective for children with moderate-to-severe Crohn's.